An unidentified company asks FDA not to publish a Warning Letter it received until the firm has exhausted its appeals and resolves other issues relating to contents of the letter.
CDER cancer drugs director Richard Pazdur, in a wide-ranging discussion with past and present advisory committee leaders, predicts that fast-track new drugs will continue to face market withdrawal, and cost-benefit will continue to not be an FDA approval factor.
Former FDA commissioner Andrew von Eschenbach says today’s complex medical problems will only be solved if medical device companies collaborate with each other and share their intellectual property.
FDA extends by three months its review of a Delcath Systems NDA for the Melblez Kit (melphalan) for injection for treating patients with unresectable ocular melanoma metastatic to the liver.
Washington Legal Foundation asks the Arkansas Supreme Court to throw out a $1.2 billion civil penalty levied by the state against Janssen for failing to include adequate warnings on labels for Risperdal between 2002 and 2006.